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INTRODUCTION 
 Hyperbilirubinemia is yellow discolouration of  sclera, skin and 
mucosa with elevated concentration of serum bilirubin. Neonates appear 
jaundiced if serum bilirubin exceeds  5 to 7 mg/dl (86-119 micro mol/l). 
Approximately  85% of term newborn and almost all  preterm newborn 
develop clinical jaundice. Chemical  hyperbilirubinemia is serum 
bilirubin greater than 2mg /dl, which is  universal in all newborns. 
According to Maisels and Gifford21 97 centile bilirubin for all healthy 
term newborn is 12.4 mg/dl for formula fed infants and 14.8 mg/dl in 
breast fed newborns.  Any serum bilirubin exceeding 17 mg/dl is 
pathologic and warrants investigation for cause. 
 Visual assessment of severity of serum bilirubin is done by Kramer 
rule . There is a cephalocaudal progression of jaundice due to maximal 
perfusion of  face, then trunk and lastly  the limbs. Apart from this  the 
affinity of binding of albumin and bilirubin varies with distance  from 
heart for  blood in circulatory system. Jaundice in head and neck 
quantitates to 4 -8 mg/dl, upper trunk  5-12 mg/dl, lower trunk and thigh 
8-16 mg/dl and palms and soles  quantitates to greater than 15 mg/dl. This 
 2
method is not reliable as examination needs bright day light and 
interpretation in dark skinned individuals is difficult. 
Factors making newborn  prone for hyperbilirubinemiaare : 
1. Increased bilirubinproduction,  
2. less effective binding and  transportation, 
3. less efficient conjugation andexcretion and  
4. Increased enterohepatic circulation.   
  
 Source of bilirubin production are RBC hemoglobin where 1 gram 
hemoglobin produces 34 mg bilirubin, and 25% bilirubin called Early 
Labelled Bilirubin produced from ineffective erythropoiesis in bone 
marrow and other heme containing proteins. 
 
 Neonatal hyperbilirubinemia can be of two forms: physiological 
jaundice and pathological jaundice. Physiological jaundice is one where 
visible jaundice appears after 24 hours, with peak bilirubin seen on 3to 5 
days of life with bilirubin levels of 12 mg/dl. In preterm neonates peak 
bilirubin rising upto 15 mg/dl on day 5 to 7of life.  
 Pathological jaundice is one that requires evaluation and treatment. 
It can be characterized by onset by 24 hours of life, rise in serum bilirubin  
> 0.2 mg/dl/hour, sign of underlying illness, any elevation of bilirubin 
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Needing phototheraphy, appearance of jaundice within 24 hours of life 
and persistence of jaundice beyond 3 weeks and direct bilirubin greater 
than 2 mg/dl. 
 Babies with physiological hyperbilirubinemia need no treatment 
and careful followup to see for the progression. Pathological 
hyperbilirubinemia is that needs evaluation , treatment and frequent 
follow up. Management of neonatal jaundice includes identification of at-
risk neonates, evaluating the cause of pathological hyperbilirubinemia, 
deciding thresholds for initiating and stopping treatment and follow-up of 
neonates with severe hyperbilirubinemia.  
 Bilirubin an antioxidant protects against freeradical injury, but still 
needs to treated to prevent patient developing severe hyperbilirubinemia 
(defined as serum bilirubin > 20 mg/dl)as it can lead to development of 
acute bilirubin encephalopathy.  If these babies are not treated they may 
present chronic bilirubin encephalopathy characterized choreoathetoid 
cerebral palsy, complete or partial sensorineural deafness, intellectual 
deficits, enamel dysplasiaand limitation of upward gaze. 
 Treatment of neonatal jaundice is closely tied to its etiology. Early 
identification of risk factors and prompt close observation of these high 
risk neonates and initiation of timely intervention is the cornerstone of 
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management. Apart from initiation of phototherapy, attention should be 
given to ensuring adequate calorie intake and hydration status to reduce 
entero hepatic circulation any drug or clinical factor  (sepsis, asphyxia, 
acidosis, temperature instability)17,6 interfering  with bilirubin 
metabolism, albumin binding and integrity of blood brain barrier. 
 Phototherapy is a modality of treatment where light of blue green 
spectrum with wavelength corresponding with peak absorption by 
bilirubin (450-460nm). Special blue lamps with wavelength of 425-475 
nm are most efficient of phototherapy. When bilirubin absorbs light three 
types photochemical reaction namely: photoisomerisation, 
structuralisomerisation and photo-oxidation occur to convert bilirubin to 
polar form to facilitate elimination of bilirubin excretion in urine and 
stool. Effective phototherapy reduces serum bilirubin at the rate of  
1-2 mg/dl every 4-6 hours to prevent complications of 
hyperbilirubinemia.  
 Estimation of extent and severity of jaundice can be done by 
estimation of transcutaneous bilirubin using  transcutaneous 
bilirubinometer. Though this is a non invasive and easy method of 
measurement of bilirubin, its estimation is unreliable with serum bilirubin 
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above 15 mg/dl, where this the group that actually needs phototherapy 
and it is this group that is not identified by this device.  
 Followup of babies during phototherapy administration is not 
reliable with bilirubinometer. Transcutaneous bilirubinometer can be used 
as screening tool but decision to treat is to be based on serum bilirubin 
estimation.  
 Serum bilirubin comprises of two parts of conjugated and 
unconjugated bilirubin. Unconjugated bilirubin is the prime component 
that is going to increase in serum in neonatal hyperbilirubinemia due to 
above said reasons. Decision to treat is based on total serum bilirubin 
without subtracting conjugated bilirubin unless its value exceeds 50% of 
total serum bilirubin. 
 Phototherapy though effective in reducing serum bilirubin  has 
short term30adverse effects like  disturbance in maternal- infant  
interaction01, disturbance of thermalenvironment, hypocalcemia15, 
disturbance of circardian rhythm9and bronze baby syndrome11 and long 
term side effects like retinal damage and retinopathy of prematurity12, 
increasing incidence of patent ductus arteriosus, chromosomal damge31, 
nevus and skin cancer. 
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 Failure of phototherapy occurs in the setting of isoimmune or other 
hemolytic disease, where adjunctive therapies like intravenous 
immunoglobulin, phenobarbitone, tin-metalloporphyrin, oral clofibrate 
and oral agar have been used to reduce the progression for need of 
exchange transfusion.    
 Exchange transfusion12 is a procedure that removes partially 
hemolysed and antibody coated red cells, removes unattached antibodies 
and replacing them with donor red cell lacking sensitizing antigen. This 
procedure being invasive with many short term and long term adverse 
effects is used as a last resort for babies with phototherapy failure and 
impending or early stages of acute bilirubin encephalopathy to reverse 
and prevent progression of brain damage.  
By doing  double volume exchange transfusion  87 % of patient 
blood volume will be replaced with fresh compatible, non hemolysed 
antibody  and bilirubin devoid  red cells. After completion of exchange 
transfusion there is reduction of serum bilirubin  to 50 -60 % of pre 
exchange value  and there  will be a rebound of serum bilirubin to 60 % 
of pre exchange value in 1 hour  due to rapid influx of serum bilirubin 
into vascular space. Further increase in serum bilirubin can occur due  
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continuous hemolysis of antibody coated RBC sequestered in bone 
marrow, spleen , senescent donor RBC and early labelled bilirubin . 
Adverse events associated with exchange transfusion are  
1. Hypocalcemia and hypomanesemia  due  binding of citrate ion to 
ionic calcium, which may manifest with ECG changes  and cardiac 
dysfunction. If documented fall in serum calcium is noticed then it 
needs  Intravenous calcium supplementation 
2. Hypoglycemia is due  to high content of dextrose in transfused 
blood causing reactive increase in endogenous insulin to cause fall 
in blood sugar. 
3. Acid base disturbance in the form of metabolic alkalosis due to 
citrate in transfused blood 
4. Hyperkalemia  due to transfusion of stored blood,  it is  avoided 
with fresh blood transfusion and washed rbc and reconstituiting 
with fresh plasma. 
5. Graft versus host disease  due to transfusion of viable WBC which 
manifest  with maculopapular rash, eosinopenia, lymphopenia, 
thrombocytopenia without other signs of immunodeficiency. This 
can be averted by transfusing irradiated blood  
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6. Thermodysregulation due of  transfusion of cold blood and can be 
averted by adequate warming blood and use of radiant warmer. 
7. Thrombovascular events in the form of thrombosis, embolism and 
vasospasm due to  catherisation of vessels. 
8. Long term events like portal vein thrombosis  and can lead to extra 
hepatic portal vein obstruction. 
 Exchange transfusion is performed using  push – pull technique, 
where sequential pulling of fixed volume of blood followed by infusing 
same volume of blood into the catheter. Volume of blood drawn will be  
5 ml for babies < 1.5 kg, 10 ml for babies with birth weight 1.5 -2.5 kg,  
15 ml for babies with birth weight of 2.5- 3.5 kg  and 20 ml for babies  
> 3.5 kg. 
 These limitation of currently available treatment modalities for a 
preventable and reversible cause of brain damage, invokes need for newer 
adjunctive therapies which reduce the adverse effects of existing 
therapies and reduce the need of invasive therapies.  
 Clofibrate, the prototype of the fibric acid derivatives, is the ethyl 
ester of p-chlorophenoxyisobutyrate, which was initially introduced for 
treatment of dysbetalipoproteinemia and hypertriglyceridemia21.  Its use 
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declined dramatically, however, after the World Health Organization 
reported that, despite a 9% reduction in cholesterol levels, clofibrate 
treatment did not reduce fatal cardiovascular events, although nonfatal 
infarcts were reduced. Clofibrate is now used in treatment of neonatal 
jaundice as it induces glucuronyl transferase10 thereby enhancing 
bilirubin conjugation and better excretion in bile. This action acts as an 
adjunct to phototherapy holds promise to reduce the phototherapy failure 
rates and duration of phototherapy. 
 The present study is to determine whether clofibrate therapy for 
neonatal jaundice decreases the duration of phototherapy, incidence of 
phototherapy failure rates and preventing further increase in serum 
bilirubin without any adverse effects. 
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REVIEW OF LITERATURE 
 Bilirubin an end product of heme metabolism is derived from 
hemoglobin , myoglobin,  cytochrome, catalase, peroxidase and free 
heme. Heme ring of heme containing compounds are oxidized in 
reticuloendothelial system by hemeoxygenase to biliverdin and release of 
carbon monoxide. Biliverdin is reduced to bilirubin by biliverdin 
reductase.  
 Bilirubin formed is nonpolar, insoluble in water,  transported to 
liver bound to albumin. Albumin  bound bilirubin  being fat soluble 
dissociates from albumin and crosses the plasma membrane and binds to 
cytoplasmic ligandin to enter the endoplasmic reticulum. Here bilirubin is 
conjugated by uridinediphosphate glucuronyl transferase to diconjugate 
form to be excreted into the bile canaliculi. This enzyme is induced by 
clofibrate to enhance conjugation and excretion. 
  Conjugated bilirubin in gastrointestinal tract is converted to 
unconjugated bilirubin by intestinal glucuronidase enzyme to enter 
enterohepatic circulation or acted by intestinal bacteriato be converted to 
urobilinoids to be excreted in stool and urine as urobilin and stercobilin 
respectively. 
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 Bilirubin in circulation is predominantly unconjugated and it is 
bound to albumin.  Bilirubin bound albumin is unable to cross the blood 
brain barrier.1 gram of albumin binds with 8.5 mg/dl of bilirubin  serum 
albumin level directly correlates to the gestational age and postnatal age 
and adult values are usually attained by 5 months of age.  
 There is structural differences in albumin configuration and this 
resolves with maturity attaining adult characteristics by10-12 months of 
age. Albumin is also the binding site for acidic drugs and in competition 
for albumin binding sites these acidic drugs displace bilirubin to enhance 
toxicity.  Bilirubin : albumin ratio exceeding 8 in term non sick neonates,   
>  7.2 in term sick neonates and  stable preterm neonates with gestational 
age above 35 weeks  upto 37 completed weeks of gestational age, > 6.8 in  
sick preterm neonates with gestational age above 35 weeks upto 37 
completed weeks of gestational age 2  increases the risk of brain damage 
and brain deposition of bilirubin. 
 Factors7 that increase susceptibility to bilirubin induced 
neurological dysfunction are asphyxia, sepsis, hyperthermia,  acidosis, 
hypoalbuminemia, acidosis, low birth weight, preterm babies, hemolysis,  
prolonged hyperbilirubinemia and caloric deprivation.  
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 Factors that enhance bilirubin deposition into brain 27 are increase  
in free bilirubin, reduction in amount or binding capacity of albumin 
which increases the precipitation of bilirubin acid in nerve cell 
membrane. Disruption of blood brain barrier and acidosis  enhance brain 
damage. 
 Bilirubin deposition occurs in  basal ganglia, pons, cerebellum. 
Deposited bilirubin causes disruption of neurotransmission, 
mitochondrial dysfunction, intracellular membrane impairment and 
interferes with cellular enzyme activity. By these activities they cause 
pigmentation and necrosis of the neural tissue Kernicterus causes 
selective yellow staining in the basal ganglia( globus pallidus and 
subthalamic nucleus).  Brainstem nuclei, especially the auditory (cochlear 
nucleus, inferior colliculus, superior olivary complex), oculomotor and 
vestibular nuclei are increasingly vulnerable. Other susceptible areas are 
the cerebellum (Purkinje cells) and the hippocampus especially the CA2 
sector. 
 Acute bilirubin encephalopathy   consists of reduced feeding, 
lethargy, variable abnormal tone (hypotonia and/or hypertonia), high 
pitched cry, retrocollis and opisthotonus, sunsetting sign, fever, seizures,  
and death. Laboratory evidence ranges from increased abnormal 
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brainstem evoked response interwave intervals I–III and I–V and 
decreased amplitude waves III and V to absent response28, and MRI 
manifest with acute abnormalities in the globuspallidus and subthalamic 
nucleus. 
 Chronic bilirubin encephalopathy ( kernicterus) is a clinical tetrad 
consisting of (1) a movement disorder consisting of not only of athetosis 
and dystonia, but also include spasticity and hypotonia, (2) auditory  
dysfunction consisting of  hearing loss and auditory neuropathy or 
auditory dyssynchrony, (3) oculomotor impairments in the form of 
impairment of upgaze and lateral gaze impairments including strabismus, 
and (4) dental enamel hypoplasia of the deciduous teeth. 
 Phototherapy is the sheet anchor in treatment of neonatal jaundice.   
Bilirubin when absorbs phototherapy light three types of photochemical 
reaction occur. They are: 1.Photoisomerisation, 2. Structural 
isomerisation, 3. Photo-oxidation.Phototherapy  light acts on bilirubin 
bound to albumin in cutaneous capillaries and interstitial space. 
 Photoisomerisation converts 4z 15z unconjugated bilirubin to less 
toxic, polar 4z 15eform  which is excreted in bile. This process is  
reversible and results in enterohepatic circulation with rapid reabsorption 
from gut. Structural isomerisation is intramolecular cyclization of 
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bilirubin to lumirubin, which contributes  2% to6% serum bilirubin 
during phototherapy resulting in bile and urine excretion. Photo-oxidation 
is least important reaction converting bilirubin to small polar products 
that are excreted in urine. 
  Factors17that determine the efficacy of phototherapy spectrum of 
light, irradiance, surface area and duration of phototherapy. The best 
spectrum of light is 425 to 475 nm, the blue green spectrum. Irradiance of 
light depends on distant from the light source and neonate. The 
phototherapy lights are placed at 20 cm from baby to increase the 
irradiance.  Surface area exposed to phototherapy is enhanced by double 
surface phototherapy and use of aluminium foils in margin of 
phototherapy unit.  
 Phototherapy  can be administered by : 1. Compact fluorescent 
light tubes  which are very effective in reducing bilirubin 2. Halogen 
lamps, though compact  cannot be kept close to baby due to risk of burns 
and spectral power produced by these lights is lower than that produced 
by compact fluorescent light tubes,3. Fibreoptic systems, is very effective 
in delivering phototherapy and they don’t have the hazard of causing 
retinal damage and are useful for home phototherapy,   4.Light emitting 
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diodes is very effective in generating adequate irradiance and spectral 
power to provide effective phototherapy. 
 Phototherapy  causes fall in serum bilirubin by 1 to 2 mg/dl every 
4-6 hrs of phototherapy. If serum bilirubin   continues to rise despite 
phototherapy to reach threshold of exchange transfusion is considered  
failure of phototherapy. To avoid this situation adjunctive  therapies have 
been developed . Intravenous immunoglobulin is used in isoimmune 
hemolytic causes wherein they act by blocking the Fc receptor to bring 
down hemolytic rate. Cost of the treatment is the limiting factor and 
useful in immune hemolysis  cases only. Other modalities are 
phenobarbitone to cause enzyme induction of uridine 
diphosphateglucuronyltransferase. This treatment has long latency period 
with 48 to 72 hours of administration to have effect on enzyme induction 
and respiratory depression and lowering serum vitamin k levels as side 
effect. Phenobarbitone on long term administration is effective in 
lowering serum bilirubin in babies with crigglar najjar syndrome type II 
and it is one of the effective therapies of this disease.  
 Oral agar, charcoal used as bilirubin binding agents  lower the 
enterohepatic circulation mediated rise in serum bilirubin. Use of oral 
agar causes increase in stool frequency to cause increase clearance of 
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intraluminal bilirubin.  But the research project are in primitive stages 
resulting in inhibition of widespread usage of these drugs. Heme 
oxygenase inhibitors like metalloporphyrins inhibit production of 
bilirubin and thereby need of phototherapy. Potency of metalloporphyrins 
depend on the nature of side chain and central metal cation.  Ethyl group 
side chain are more potent than any other side chain. However  these 
donot bind molecular oxygen, so they are not metabolically degraded. 
There is unceratinity in form metalloporphyrin to  be used like  tin, zinc, 
cobalt form and data regarding side effects and tolerability are limited. 
These metalloporphyrins are to be administered intramuscularly and their  
effectiveness depends on the dosage administered.   
 Clofibrate used in neonatal jaundice as a enzyme inducer has 
shown in preliminary studies to reduce the failure rates of phototherapy 
and  duration of phototherapy. The dose needed to achieve this is of 
single dose thereby obviating the problem of compliance. This drug is 
also in its preliminary stages regarding the correct dosage for best effect 
and least possible adverse effect, its use in immune hemolytic jaundice 
which is the prime cause of phototherapy failure. This invokes further 
research in this subject. 
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  Phototherapy though the most effective way to treat neonatal 
jaundice is now found to have significant adverse effects these effects are 
of short term and long term nature. Short term effects is that it  affects 
mother infant bonding. Phototherapy separates neonates from mothers, 
which might interfere with establishing parent–child bonding in the era 
where the concept rooming in and mothering in is promoted in baby 
friendly hospital initiative. Fluorescent lamps routinely used in 
phototherapy changes the thermal environment of infants, which leads to  
increased insensible water loss, hypothermia, hyperthermia, and 
dehydration. Phototherapy can lead to decreased total and ionized 
calcium levels, especially in preterm neonates. This effect is attributed to 
increased urinary calcium excretion . In addition, light can affect calcium 
homeostasis by inhibiting pineal secretion of melatonin and consequently 
leading to hypocalcemia. Decreased  plasma levels of  melatonin, alters 
the  normal  circadian rhythms and leading to abnormal behaviors such as 
frequent crying and jitteriness. 
 Phototherapy affects the Th-2/Th-1 switch, causing allergic 
diseases during childhood and later in life. Phototherapy can significantly 
increase the levels of cytokines, including TNF-alpha, IL-1 beta, and IL-
8, but decrease the level of IL-6  This change of cytokine levels is 
considered to be the principal cause of Th-2/Th-1 switch disorder. 
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Phototherapy induced chromosomal and DNA breakage induces defective 
lymphocyte function and defective TH2/TH1 switch.  
 Penetration is enhanced in neonates  who are being exposed to a 
higher  spectral irradiance of phototherapy. The light photon causes the 
relaxation of aortic smooth muscle  through the activation of the nitric 
oxide–cyclic GMP pathway and Ca2+-dependent K+ ion channels. This 
causes reopening of ductus arteriosus.  Photon absorption is dramatically 
increased in the retina during blue light exposure, increasing the 
susceptibility to light-induced cell death in the retina  to cause retinal 
damage. Bilirubin plays a role as an antioxidant, so ROP might be 
mitigated by bilirubin. 
 With the above side effects  and chance of failure in certain group 
patients it obviates the need of new form of therapy that would be 
adjunctive or substitute or prevent patient from exposed to phototherapy. 
Of the above said adjunctive therapy clofibrate promises to effective, safe 
readily available modality with single dosing eliminating compliance 
issues. 
 Clofibrate the prototype of the fibric acid derivatives, is the ethyl 
ester of p-chlorophenoxyisobutyrate. In 1962, Thorp and Waring reported 
that ethyl chlorophenoxyisobutyrate lowered serum lipid levels in rats. In 
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1967, the ester form clofibrate was approved for use in the United States 
and became the most widely prescribed hypolipidemic drug. Its use 
declined dramatically after the World Health Organization reported that, 
clofibrate treatment did not reduce fatal cardiovascular events, although 
nonfatal infarcts were reduced. Fibrates reduce triglycerides through 
peroxisomal proliferator activation receptor alpha -mediated stimulation 
of fatty acid oxidation, increased lipoprotein lipase synthesis, and reduced 
expression of apoC-III. An increase in lipase would enhance the 
clearance of triglyceride-rich lipoproteins. A reduction in hepatic 
production of apoC-III, which serves as an inhibitor of lipolytic 
processing and receptor-mediated clearance, would enhance the clearance 
of VLDL. Fibrate-mediated increases in HDL-C are due to PPARa 
stimulation of apoA-I and apoA-II expression, which increases HDL 
levels. 
 Clofibrate treatment also increases the hepatic conjugation of UCB 
Via induction of  glucuronyl transferase enzyme in liver. Its potency in 
enzyme induction is three times that of phenobarbitone. Clofibrate10 
treatment in Sprague-Dawley rats increased glucuronyltransferase activity 
and resulted in an 84% increase in the hepatic clearance of  
IV-administered  unconjugated bilirubin. This drug is proposed to reduce 
the duration of phototherapy and failure of phototherapy. 
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 Lindenbaum et al.19,20published the first randomized placebo-
controlled trial with clofibrate in 1981, involving 93 full-term neonates 
with physiological jaundice. Of these 93 neonates, 47 received one  oral 
dose of clofibrate, which significantly lowered plasma UCB levels from 
the 6th hour after administration and curtailed the duration of jaundice. A  
study in 89 preterm neonates showed comparable results, including 
indications for a dose-response relationship: the hypobilirubinemic effect  
correlated with the plasma level of clofibrate. 
 Zahedpasha et al did a randomized trial in healthy term newborns 
with birth weight above 2.5 kg  and randomized 60 babies into two 
groups of 30 babies  excluding babies with hemolytic disease of newborn.  
The baseline variables in term of sex distribution , mean age at start of 
phototherapy, and mean bilirubin at start of phototherapy were not 
significantly different between two groups. They concluded that 
clofibrate had significant reduction in duration of phototherapy and and 
mean bilirubin at 24 and 48 hours of treatment. 
Eghbalian et al performed a randomized trial in 30 term babies in 
clofibrate  group and 30 babies in control group.  These babies were 
similar in baseline serum bilirubin. They found that clofibrate group 
patient had significant reduction in duration of  phototherapy,and mean 
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bilirubin at 24 and 48 hours after start  of phototherapy. They concluded 
that clofibrate is effective in treatment of neonatal jaundice  in term 
neonates. 
Fallah et al performed a randomized trial in term newborns with 
birth weight  > 2.5 kg and there 30 babies in each group. In this study 
clofibrate  was administered orally at a dose of 5o mg/kg at the start of 
phototherapy. The mean bilirubin at the start of phototherapy was similar 
in both group. They measured two outcomes, and found that clofibrate 
group had significant reduction in duration of phototherapy where the 
clofibrate group needed treatment for 30 hours against 46 hours in 
phototherapy alone group  and  2 patients had episodes of loose stool of  
reported side effects in clofibrate group. It was found that clofibrate even 
at a dose of 50 mg/kg had same effect in decreasing the duration of 
treatment. 
 Habibi et al performed a randomized trial with 52 babies in total , 
with 26 babies in each group. They performed  a randomized trial in term 
babies with birth weight > 2.5 kg. The baseline characteristics of  mean 
birth weight, sex distribution, mean hours of life at start of phototherapy 
and mean baseline bilirubin at start of phototherapy were  similar in either 
groups. Babies were administered 100 mg/kg clofibrate at start of 
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phototherapy and the outcomes measured were duration of phototherapy, 
peak bilirubin and adverse  events occurrence. It was found serum 
bilirubin levels after 24 hours of start of treatment in clofibrate was lower 
than control group and decrease in duration of phototherapy without any 
adverse events. 
Sharafi et al had their mean duration of phototherapy in their study 
to be 72 hours in clofibrate group and 76.80 hours in control group, in a 
study performed to study the effect of clofibrate in neonatal jaundice 
involving 60 babies with 30 babies in each group. The results also 
showed decrease in mean serum bilirubin at 24 and 48 hours after start of 
phototherapy. This study was performed in 60 term babies with weight 
above 2.5 kg and 50 mg/kg dose was administered and all the babies were 
at home therapy 
 Three randomized controlled trials34,35, each involving 60 full-term 
neonates, compared the use of clofibrate and phototherapy with the use of 
phototherapy alone. Clofibrate, as add-on treatment to phototherapy 
accelerated the decrease in serum total bilirubin concentrations and it  
was found in all of these trials to decrease the duration of phototherapy. 
 Clofibrate has been tested in different situations of neonatal 
jaundice. In 2011morteza et al    conducted a study to evaluate the 
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therapeutic effect of clofibrate in neonatal hyperbilirubinemia in  
52 newborns . Drug increases liver bilirubin clearance rate to 100% 
within 6 hours and the study concluded that clofibrate was effective in 
reducing  mean serum bilirubin values at 24 and 48 hours after start of 
phototherapy in term newborns with non hemolytic neonatal jaundice. 
Yadollah et al  assessed the efficacy of clofibrate in neonatal jaundice in 
40  patients with glucose 6 phosphate dehydrogenase deficiency. The  
mean serum bilirubin was significantly lower during phototherapy in 
patients with single dose of clofibrate of 100 mg/kg. They concluded that 
clofibrate induces a faster decline in serum total bilirubin level, a shorter 
duration of phototherapy and hospitalization without any side effects in 
full term G6PD deficient neonates with jaundice.  
 Zahedpasha et al did another randomized trial to study the duration 
of treatment, peak bilirubin, adverse events and exchange transfusion 
performance in term neonates with birth weight above 2.5 kg and 
included babies with  glucose 6 phosphate dehydrogenase deficiency 
babies and excluding babies with blood group incompatibility and they 
found that clofibrate brought about significant reduction of phototherapy 
duration,  failure of phototherapy and peak bilirubin. 
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  Studies including hemolytic disease of newborn are very few. 
Since glucose 6 phosphate dehydrogenase deficiency which induces 
spontaneous hemolysis in severe forms of the disease and hemolysis on 
exposure to triggering factors and stressful situation in milder disease and 
this being very common in Middle East Asian region.  This study was 
performed by Zahedpasha in Iran showed significant reduction in 
duration of phototherapy. Apart  from this Flores –nava  did trial 
involving 45  babies including both term and preterm babies with ABO 
and Rh incompatibility using 100 mg/kg clofibrate  and they found 
significant decrease in duration of phototherapy and need of exchange 
transfusion. Similarly Lindenbaum studied 93 babies  in study and only 
term babies were included including ABO and Rh incompatibility. The 
assessed the peak bilirubin and need for exchange transfusion and found 
significant reduction in both outcomes observed. This shows that there is 
paucity of data involving   hemolytic disease of newborn and this shows 
need to study in large sample of babies with Rh and ABO incompatibility 
in our setting. 
 Ashraf et al conducted  a randomized double blinded placebo 
controlled trial on efficacy of clofibrate in neonatal hyperbilirubinemia in 
preterm newborn babies.  They had concluded that effect of clofibrate on 
treatment of jaundice was not significant difference in peak bilirubin 
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between the two groups, though duration of phototherapy has been 
decreased significantly in clofibrate groups. 
Sakha et al performed a randomized controlled trial involving 30 
babies in clofibrate group and 30 babies in phototherapy group in term 
and late preterm babies. The babies had comparable baseline 
characteristics in either group with regards to gestational age , mean 
bilirubin at start of phototherapy and mean age in hours of life at start of 
phototherapy. Here babies received 100 mg/kg of clofibrate within  
12 hours of phototherapy. They measured outcomes of peak bilirubin, 
duration of phototherapy, rebound jaundice and adverse events following 
phototherapy  administration. They concluded that there was significant 
decrease in mean serum bilirubin at 24 and 48 hours after of phototherapy 
and good decrease in  duration of phototherapy. There was no significant 
rebound increase in serum bilirubin and no reported side effects. 
 Sedigheh et al  did a randomized  controlled trial involving  68  
healthy late pre-term newborns  with non-hemolytic jaundice and 
neonates that did not need urgent exchange transfusion. They analysed 
the   bilirubin values after 48 hours of phototherapy administration and 
duration of phototherapy and  they  found that   mean duration of 
phototherapy was 64 .32 hours   in the study group in comparison with 
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control group with 87.84 hours with significant reduction in duration of 
phototherapy and  mean TSB 48 hours after phototherapy  was  8.6 mg/dl  
in clofibrate  group and  it was 10.94 mg /dl  in phototherapy group with 
no significant difference in mean bilirubin at 48 hours of treatment.  This 
study though included stable preterm newborn, did not include babies 
with hemolytic disease. 
Caballero-noguez et al performed and randomized trial involving 
12 babies in clofibrate group and 9  babies in phototherapy involving 
preterm newborns with gestation age above 28 weeks . They measured 
outcomes  such as adverse effects and need of exchange transfusion and 
there was no reported adverse effects and  no baby needed exchange 
transfusion. Drawback of this was they failed to measure the duration of 
phototherapy  and peak bilirubin  and the sample size was small , making 
the need of study with large sample size . The positive aspect of the study 
was that they included preterm newborns of gestation age upto 28 weeks 
and the study could suggest that it was safe even in preterm newborns. 
Thus uptodate there is no well performed study on preterm to suggest the 
effectiveness of this drug in preterm neonates 
 Clofibric acid is the main metabolite of clofibrate, which has the 
effective plasma concentration of 140µg/mL for jaundiced neonates. In 
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humans, most of the plasma clofibric acid is in  bound  state to albumin. 
Decreased level of albumin in preterm infants will lead to increased free 
form of clofibric acid, which  will facilitate  rapid clearance of clofibric 
acid and results in lower plasma levels of clofibric acid. This invokes the 
need of higher dose in preterm and sick neonates with low serum 
albumin. Clofibrate has been used in different dosages from 25 mg/kg 
single dose to 100 mg/kg single dose. There has not been significant  
variation in results. Moslehi25 et al performed a randomized controlled 
trial to  study the effect of low dose (25mg/kg) in neonatal jaundice. They  
randomized patients into three groups where one group received  
25 mg/kg of clofibrate, another group received 50 mg/kg and last group 
received only phototherapy. The mean serum bilirubin was significantly 
lower in either clofibrate groups and mean duration of phototherapy was 
significantly lower in  either clofibrate group. They concluded that  lower 
doses of clofibrate can be used with the same therapeutic efficacy in 
reducing TSB levels in term infants and there was no side effects in either 
group of clofibrate treatment . 
 Side effects with clofibrate drug therapy have noticed in long term 
therapy for treatment of hyperlipidemia. The reported adverse effects 
have  been Gastrointestinal side effects occur in up to 5% of patients. 
Other side effects are reported infrequently and include rash, urticaria, 
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hair loss, myalgias, fatigue, headache, impotence, and anemia. This has  
been with chronic drug intake. In treatment of neonatal jaundice single 
dose is used and dosage used is less than the dose for treatment of 
hyperlipidemia.Tao29 et al had conducted a systematic review on  
13 randomised controlled trials and 2quasi randomized controlled trials 
involving 867 neonates involving neonatal jaundice, where varying doses 
of clofibrate used showed no significant side effects in the follow up 
period of 2 weeks to 2months, except 1 case of cholestasis. The follow up 
duration was short in various studies and none of the above said  side 
effects have been reported in the single dosing in infants. 
 Cochrane review12 done by Gholitbar M et al to evaluate the 
efficacy of clofibrate in neonatal jaundice to determine the following 
outcomes :  
1.  Mean change in bilirubin levels (mg/dL or µmol/L) over 24 hours, 
 48 hours, 72 hours.  
2.  Mean duration of treatment with phototherapy (hours),  
3.  Number of exchange transfusions needed,  
4.  Any adverse effects of  clofibrate,   
5.  Bilirubin encephalopathy,  
6.  Neonatal mortality. 
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 This review was conducted involving  Fifteen studies  of which 
two included preterm neonates and 13 had  included term neonate.  All 
the studies were conducted in Iran except one study. They concluded that 
there was reduction in peak bilirubin at 48 hours and duration of 
phototherapy in preterm newborns. In term newborns also there was  
reduction in duration of phototherapy, mean bilirubin was  reduced at  
24 hours and 48 hours after start of phototherapy. They also analysed the 
data on efficacy of clofibrate at different doses and found studies in term 
newborns at doses of 50 mg/kg and 25 mg/kg and found that they were 
effective in reducing the duration of phototherapy and mean bilirubin at 
24 and 48 hours of phototherapy. There was also significant reduction in 
need of exchange transfusion and found no significant adverse effects. 
 They concluded that evidence that clofibrate in combination with 
phototherapy has a beneficial effect on the duration of phototherapy 
needed for neonates with hyperbilirubinaemia and rates of exchange 
transfusion were quite low with only three neonates requiring an 
exchange transfusion in all the studies, which is to be expected with the 
effectiveness of phototherapy  There are limitations in advocating routine 
use of clofibrate as an adjunct to phototherapy as there is limitation of 
date on long term  safety profile of the drug, its efficacy is yet to be tested 
in sufficient cases of immune hemolytic jaundice. There are no data  to 
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show whether  the drug  treatment modifies the rate of kernicterus or 
long-term neuro developmental impairment due to bilirubin 
encephalopathy or risk of death. 
From the above  review clofibrate  is effective at lower dose and 
has reported no side effects  and at the same stage  is very effective in 
treatment neonatal jaundice. Data is still lagging in studies outside Iran 
and treatment of preterm babies and those with hemolytic disease.  
This obviates the need of studies in large sample with inclusion of 
isoimmune jaundice with need for long term followup  of subjects to 
study the safety of this drug. After the review of literature,  justifying that 
immaturity of hepatic system in conjugating bilirubin plays  one of the 
important causes of presentation  of neonatal jaundice and this opens new 
avenues of research needed to find adjunctives to phototherapy in 
treatment of jaundice. 
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AIMS AND OBJECTIVES OF THE STUDY 
 To assess the efficacy  of clofibrate with phototherapy  versus  
Phototherapy in treatment of neonatal hyperbilirubinemia  
Outcomes measured: 
1.  peak bilirubin    
2. duration of phototheraphy 
3.  need of exchange transfusion 
RESEARCH HYPOTHESIS 
 Adjunctive usage of clofibrate with phototherapy reduces the 
duration of phototherapy,  reduces the  occurrence of failure of 
phototherapy by induction of enzyme glucuronyl transferase and prevents 
the rise of serum bilirubin during phototherapy treatment. 
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MATERIALS AND METHODS 
STUDY DESIGN  
Double blinded randomized controlled  trial 
STUDY PERIOD 
January 2012 to November 2012 
STUDY POULATION  
 Intramural and extramural newborns admitted for neonatal jaundice 
in Neonatal Intensive Care Unit, Government Kilpauk Medical College 
Hospital, Chennai-10. 
INCLUSION CRITERIA 
 Term neonates with birth weight> 2.5 kg with total serum bilirubin 
values  meeting the threshold for phototherapy according to age specific 
nomogram by American Academy of Paediatrics2 for phototherapy. 
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EXCLUSION CRITERIA 
1. preterm 
2. newborn with sepsis, asphyxia, shock 
3. congenital anomalies 
4.  small for gestation/ intrauterine growth restriction 
5.  neonatal cholestasis  
6.  Inborn errors of metabolism 
7.  neonates already started on phototherapy before referral 
8.  neonates with renal or liver disorders 
9.  neonates with coagulation disturbances 
10.  neonates with acid base disturbance, electrolyte disturbance 
11.  neonates with features of intrauterine infection 
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GROUPS ASSIGNED 
1.  Clofibrate with  phototherapy 
 
2.  Phototherapy 
DRUGS USED 
 Single dose of 25 mg/kg clofibrate  tablet dissolved  in expressed 
breast milk given at the start of phototherapy per oral route  
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METHODOLOGY 
 Neonates found to be icteric on clinical examination  were 
subjected to serum bilirubin evaluation and those babies with serum 
bilirubin crossing the cut off value for phototherapy by AAP nomogram 
for phototherapy or exchange transfusion were assessed for exclusion 
factors. If exclusion factors were absent  they were enrolled into the after 
obtaining written and informed consent. These babies were randomized to 
either of the group using randomization table. Neonates of the clofibrate 
group were given single oral dose of clofibrate 25 mg/kg dissolved in 
expressed breast milk fed through paladai before the start of 
phototherapy. Neonates of the control group were given 0.5 ml of 
multivitamin drops dissolved in expressed breast milk fed through 
paladai. Babies of both the group were subjected phototherapy at a 
distance of 20 cm under phototherapy unit with 6 fluorescent lamps of 
blue light spectrum continuously with interruption of phototherapy only 
during breast feeding. 
 Babies were continuously monitored clinically and evaluated for 
development of side effects of either therapy in both groups. Serum 
bilirubin was monitored at the start of phototherapy and every 12 hours  . 
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Phototherapy was stopped when serum bilirubin fell 2mg/dl below age 
specific threshold according to AAP nomogram.  
 Neonates whose bilirubin continued to rise despite intense 
phototherapy were subjected to exchange transfusion when bilirubun 
level crossed the threshold for exchange transfusion as per AAP 
nomogram. 
 At the start of phototherapy  neonates were evaluated for their 
blood group, maternal blood group, coombs evaluation, peripheral smear 
evaluation, liver function test, renal function test and daily weight 
monitoring. Serum bilirubin was monitored for 12 hours after stopping 
phototherapy and if no rebound rise occurred ,babies were discharged  
24 hours after stopping phototherapy. Babies discharged were followed 
up 1 week after discharge for weight gain ,  features of cholestasis, 
feeding and bowel pattern and  clinical evaluation were performed. 
 Data regarding the sex, birth weight, hour/day of life, maternal and 
baby blood group, bilirubin at the start of treatment and peak bilirubin 
were recorded. Duration of phototherapy, failure of phototherapy, if any 
were recorded. Monitoring and follow up data were recorded. Babies 
were managed as per standard protocol and were assessed frequently for 
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development of any complication. Data obtained were analyzed for 
statistical significance.   
 Discrete variables were analyzed by chi-square test and continuous 
variables by z test. P value < 0.05 was considered  as statistically 
significant. 
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RESULTS 
 The study was conducted in newborns admitted as neonatal 
hyperbilirubinemia  in the Neonatal Intensive Care Unit (NICU), 
Department of Paediatrics, Kilpauk Medical College & Hospital, 
Chennai. Both intramural and extramural babies were included in this 
study. Study was conducted over a  11 months period, extending from 
January 2012 to november 2012. 
 During this study period 415 neonates were treated for 
hyperbilirubinemia with phototherapy. Of this 198 cases met the 
inclusion criteria and were enrolled into the study. 99 babies were 
randomized to clofibrate with phototherapy  group and  99 babies were 
randomized to phototherapy alone group. Babies in the clofibrate with 
phototherapy were given single dose of clofibrate 25 mg/kg at start of 
phototherapy and were continued on phototherapy as per protocol.  
 Babies were monitored with serum bilirubin every 12 hours and 
were monitored for any complication in either group. Babies were 
discharged after 24 hours of stop of phototherapy and babies were 
followed up after 1 week. There were no babies who were lost to follow 
up. 
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Group No .of neonates 
Clofibrate with phototherapy 99 
phototherapy 99 
 
no of neonates
clofibrate with phototherapy
phototherapy
 
Fig 1: number of neonates in either groups 
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SEX DISTRIBUTION 
 In phototherapy group there were 54 male babies and 45 female 
babies. In clofibrate group there were 56 male babies and 43 female 
babies 
 
Group Male(%) Female(%) 
Clofibrate with 
phototherapy 
56 (56.56%) 43(43.43%) 
phototherapy 54(54.54%) 45(45.45%) 
total 110(55.55%) 88(45.45%) 
     
CHI SQUARE TEST 
 
 value  Degree of 
freedom 
P value 
Chi square 0.081 1 p>0.05 
No. of valid 
cases 
198   
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Fig2: sex distribution in either groups 
 Though there were more number male babies in either group but 
the sex distribution was statistically insignificant with p value> 0.05. The  
increase in number of males presenting jaundice substantiates the fact  
that male  babies  are at increased risk of jaundice. 
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HOURS OF LIFE  AT START OF PHOTOTHERAPY 
 The mean hours of life in either  group at start of phototherapy is  
depicted in table below. 
group Mean hour of life(+/- SD) 
Clofibrate with phototherapy  58.91 hours(+/-18.39) 
phototherapy 60.54 hours(+/-16.07) 
  
 The mean  hours of life at start of phototherapy was 58.91 hours 
and 60.54 hours in clofibrate and phototherapy respectively. 
 When analysed with Z test there was  no significant  difference in 
either group with pvalue>0.05 
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Fig3: mean age in hours at start of phototherapy in either groups 
 There were 99 babies in each group and they were enrolled into 
study when their respective serum bilirubin crossed age specific threshold 
for phototherapy by AAP nomogram for start of phototherapy.Babies 
were predominantly presenting in the age group of 24-72 hours And 
babies those presented in the first 24 hours were those with blood Group 
incompatiblity. Age in hours at the start of phototherapy is depicted in 
table below for babies of either group. 
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Hours of life Clofibrate with 
phototherapy 
phototherapy Total 
< 24 hrs  1(1.01%) 1(1.01%) 2(1.01%) 
24- 72 hrs 81(81.81%) 85(85.85%) 166(83.83%) 
72-120 hrs 17(17.17%) 13(13.13%) 30(15.15%) 
  
 
Fig4: age distribution ranges in either groups at start of 
phototherapy 
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CHI QUARE TEST 
 value Degree of 
freedom 
P value 
Pearson chi 
square test 
0.192 2 p>0.05 
No. of valid case 198   
 
 There is no significant difference in number of patient started 
phototherapy according to hours of life at start of phototherapy. 
 Number of patient with blood group incompatibility in both groups 
is presented in following table. Though babies were not evaluated for 
minor blood group incompatibility ABO incompatibility was the common 
form of incompatibility.  
Group Rh 
incompatiblity 
ABO 
incompatiblity 
Total 
Clofibrate with 
phototherapy 
3(3.03%) 22(22.22%) 25(25.25%) 
phototherapy 1(1.01%) 14(14.14%) 15(15.15%) 
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Fig 5: blood group incompatibility in either group 
CHI SQUARE TEST 
 value Degree of 
freedom 
P value 
Pearson chi 
square test 
1.84 1 p>0.05 
No . of valid 
cases 
198   
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 Though there was increased number of patients in  clofibrate group 
with blood group incompatibility there was no statistical significance in 
number of patient with blood group incompatibility in  either groups. 
DURATION OF PHOTOTHERAPY 
 The mean duration of phototherapy in clofibrate groupwas 40.73 
hours and it was 50.85 hours and this data is depicted in the  table below . 
Group Duration of phototherapy in 
hours(+/-SD) 
Clofibrate with phototherapy 40.73(+/-8.1) 
phototherapy 50.85(+/-7.3) 
 
 These results were analysed using Z test. The Z score obtained 
was- 9.12 in single tailed Z test and  p value <0.001 was  statistically 
significant. There was statistically significant reduction in duration of 
phototherapy in clofibrate group than the phototherapy group.  
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Fig 6: duration of phototherapy in either groups 
 In clofibrate with phototherapy group data regarding number of 
patients needing  different duration of phototherapy is depicted in table 
below 
CLOFIBRATE WITH PHOTOTHERAPY GROUP  
Duration of phototherapy No.  of babies 
< 24 hours 10(10.11%) 
24-48 hours 71(71.72%) 
48- 96 hours 18(18.19%) 
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Fig 7 : duration of phototherapy in clofibrate with phototherapy 
 In phototherapy alone group number of patient needing  different 
duration of phototherapy is depicted below. 
Patients in phototherapy group 
Duration of phototherapy No. of babies 
24-48 hours 55(55.56%) 
48-96 hours 43(43.44%) 
96 -120 hours 1(1.01%) 
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Fig 8: duration of phototherapy in phototherapy group 
 There was no patient who needed phototherapy for less than 24 
hours and 1patient needed phototherapy for 120 hours with exchange 
transfusion in the phototherapy group. 
 Data regarding duration of phototherapy in both clofibrate with 
phototherapy and phototherapy were analysed . There was  significant 
decrease in duration of phototherapy and there was  significantly 
increased number of patient needing phototherapy for less  than 48 hours 
in clofibrate with phototherapy group. The data is  presented in following 
table 
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Duration of 
phototherapy 
Clofibrate with 
phototherapy 
phototherapy 
< 24hours 10 0 
24-48 hours 71 55 
48-96 hours 18 43 
>96 hours 0 1 
 
Pearson chi 
square test 
15.274 Degree of 
freedom 
3 P<0.01 
No. of valid 
cases 
198   Statistically 
significant 
 
 
 
 
 
 52
 
Fig 9:duration of phototherapy in either group 
 There was statistically significant decrease in duration of 
phototherapy in clofibrate group  with predominant of patient needing 
phototherapy less than 48 hours. 
RELATION OF  DURATION OF PHOTOTHERAPY  TO HOURS  
OF LIFE AT INITIATION OF PHOTOTHERAPY 
 In patient   needing phototherapy for 24 to 48 hours in relation to 
hours of life at start of phototherapy were analysed and was not 
statistically significant( pvalue > 0.05). 
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Patients needing phototherapy for 24-48 hours 
Hours of life at start 
of phototherapy 
Clofibrate with 
phototherapy 
Phototherapy 
< 24 hours 1(100%) Ni1 
24-72 hours 57(70.3%) 47(55.29%) 
72 -120 hours 13(76.4%) 8(61.5%) 
 
Fig10: duration of phototherapy- 24to 48 hours at  
various hours of life 
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DURATION OF PHOTOTHERAPY – 24 TO 48 HOURS 
Pearson chi 
square test 
1.268 Degree of 
freedom 
2 P value 
>0.05 
No.of valid 
cases 
126    
 
 In patients needing 48 to 96 hours of phototherapy when analysed 
with regards to age in hours of life at start of phototherapy the following 
data were obtained. 
Patients needing phototherapy for 48 -96 hours 
 
Hours of life 
 
Clofibrate with 
phototherapy 
 
Phototherapy 
<24 hours nil 1(100%) 
24-72 hours  17(20.98%) 37(43.52%) 
72 -120hours 1(5.8%) 5(38.46%) 
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Fig11:duration of phototherapy 48-96 hours at various hours of life
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CHI SQUARE TEST 
 
  Degree of 
freedom 
P value Result 
Pearson chi 
square test 
o.755 2 P> 0.05 Statistically 
insignificant 
No.of valid 
cases 
61    
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 PEAK BILIRUBIN  
 Peak bilirubin value of both the group were analysed in both  the 
groups.  In all cases except one case which went to be treated  with 
exchange transfusion, in none of the case there was increase  in serum 
bilirubin after start of phototherapy.  Peak bilirubin  corresponded to 
bilirubin at start of phototherapy. Data of peak  bilirubin is given in the 
following table  
Clofibrate with phototherapy 18.63 
phototherapy 18.25 
 
 This result analysed by Z test was found to be statistically not 
significant (p value>0.05 ) with Zscore of 1.01. The data on various range 
of peak bilirubin is presented in following table. 
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Peak bilirubin ranges 
Bilirubin range phototherapy Clofibrate with 
phototherapy 
10-15 1(1.01%) 1(1.01%) 
15-20 96(96.97%) 94((94.95%) 
20-25 1(1.01%) 4(4.04%) 
25-30 1(1.01%) Nil 
 
Fig 13:peak bilirubin  values 
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Chi square 
test 
2.821 Degree of 
freedom 
  
No. of valid 
cases 
198 3 p>0.05 Statistically 
insignificant 
 
 There was no statistically significant difference in number patient  
presenting their peak bilirubin between the two groups ( pvalue>0.05). 
RELATION  OF HOURS OF LIFE AT START OF 
PHOTOTHERAPY WITH PEAK BILIRUBIN 
 The relationship of duration of life at start of phototherapy  and 
peak bilirubin was analysed .Data is presented in the following table  and 
data was found to be statistically insignificant( p value >0.05). 
For babies with < 24 hours of life at start of phototherapy 
 Peak Bilirubin  10-15  
clofibrate with 
phototherapy 
1(100%) Pvalue>0.05 
phototherapy 1(100%)  
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 There was only one baby in each group who were started  
phototherapy at < 24 hours of life and there was no significant  difference 
in number of patient presenting with hyperbilirubinemia in babies < 24 
hours  
For babies with 24 -72 hours of life at start of phototherapy 
 10-15 15-20 20-25 25-30 
Clofibrate 
with 
phototherapy 
Nil 78(93.97%) 3(6.02%) nil 
phototherapy nil 83(97.65%) 1(1.17%) 1(1.17%) 
 
    CHI SQUARE TEST 
Pearson chi 
square test 
3.57 Degree of  
freedom 
3 
No.of valid 
cases 
166 p>0.05  Not significant 
 
 There were 81 babies in clofibrate group and 85 babies in 
phototherapy group and predominantly were presenting with peak 
bilirubin of 15 -20 mg /dl , where 96% patients of this group of babies at 
24 -72 hours of life are in peak bilirubin range of 15 -20 mg/dl. On 
analysis p value (>0.05) was statistically insignificant. 
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Fig 12: 24-72 hours of life at start of phototherapy  
and their peak bilirubin 
 
 For babies at 72 -120 hours of life at start of phototherapy data is  
provided in table below. 
group 10-15 15-20 20-25  
Clofibrate with 
phototherapy 
Nil 16(94.11%) 1(5.89%) Pvalue>0.05 
Phototherapy nil 13(100%) Nil Insignificant 
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CHI SQUARE TEST 
Pearson chi 
square test 
2.0690 Degree of 
freedom 
2 
No.of valid 
cases 
30 p> 0.05  Not significant 
 
 
Fig 13: 72-120 hours of life at start of phototherapy and  
their peak bilirubin 
 There were 30 babies presenting in 72 -90 hours of life . Here 97 % 
of babies were in peak bilirubin range of 15-20 mg/dl. Of  these  16 
babies of clofibrate group and 13 babies of phototherapy group  were in 
peak bilirubin range of 15-20 mg/dl. 
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RELATION OF PEAK BILIRUBIN  WITH DURATION OF  
PHOTOTHERAPY 
 Relationship of babies peak bilirubin and duration of phototherapy 
was analysed and the results are in following tables Data of babies with 
peak bilirubin between 10 -15 mg/dl is provided in  following table 
Group 24 -48 hours 48 -96 hours  
Clofibrate with 
phototherapy 
1(100%) Nil P value >0.05  
phototherapy Nil 1(100%) insignificant 
 
 There were one baby in each group and  there was no significant 
difference in either group  of babies   
 Data for babies with peak bilirubin between 15-20 mg/dl is 
presented in following table.  
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Group <24 hours 24-48hours 48-96 hours Pearson 
chi square 
Clofibrate 
with 
phototherapy 
10(10.41%) 69(71.87%) 15(15.62%) 24.721 
phototherapy nil 54(57.44%) 42(44.68%) P<0.001 
 
CHI SQUARE TEST 
PEARSON CHI 
SQUARE TEST 
24 .721 Degree of 
freedom 
2 
No.of valid cases 190 P value <0.001 significant 
 
 Here there were 190 babies in total, of which 96 babies  were in 
phototherapy group and 94 babies in clofibrate group. 64% of  babies 
were needing  phototherapy for 24 -48 hours in total and 71.8%  of babies 
were in clofibrate group and 57.5 % in phototherapy group  were needing 
phototherapy group for 24-48 hours. There was a  statistically significant 
reduction in duration of phototherapy in patients  with peakbilirubin15-
20mg/dl. 
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Fig 10: relation of peak bilirubin 15 -20 mg/dl  
and duration of phototherapy 
 Data for babies with peak bilirubin 20-25 mg/dl is presented in  
following table and there were 5 babies in total of which 4 babies were in 
clofibrate group and 1 baby in phototherapy group. There was no  
significant difference in duration of phototherapy in those babies with  
peak bilirubin of 20 -25 mg/dl.  
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Group <24hours 24-48 
hours 
48-96 hours P value 
Clofibrate 
with 
phototherapy 
Nil 1( 25%) 3(75%) P>0.05 
phototherapy Nil Nil 1(100%) Insignificant 
 
CHI SQUARE TEST 
Pearson chi 
square test 
2.8 Degree of 
freedom 
1 
No.of valid 
cases 
5 p> 0.05   Not significant 
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Fig15: peak bilirubin 20-25 mg/dl and duration of phototherapy 
 
FAILURE OF PHOTOTHERAPY/ NEED OF EXCHANGE 
TRANSFUSION 
 There was 1 case who needed exchange transfusion in  
phototherapy group whowas started phototherapy at 39 hours of life  with 
peak bilirubin 25.4 and baby had ABO incompatibility needing  
phototherapyfor 96 hours. This baby had ABO blood group  
incompatibility and was coombs positive and had elevated retic count  
with plenty of spherocytes in smear. Baby had failure of phototherapy  
despite starting on double surface phototherapy This data is presented  in 
following table  There was no statistical significance in the performance 
of exchange  transfusion. 
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 Exchange 
transfusion 
done 
Exchange 
transfusion 
not done 
Pvalue 
Clofibrate with 
phototherapy 
Nil 99(100%) p>0.05 
phototherapy 1(1.01%) 98(98.99%) Insignificant 
 
CHI SQUARE TEST 
Pearson chi 
square test 
2.98 Degree of 
freedom 
1  
No.of valid 
cases  
198 p> 0.05 insignificant 
 
 Babies  were followed up  during hospital stay, at  discharge and at 
1 week following discharge and they had no  complication in either 
group. Babies were gaining weight adequately. 
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DISCUSSION 
 Neonatal jaundice is a common clinical entity with common  
occurrence between 25 hours and 144 hours in 70% -80 % of term 
newborns and of these 20 % to 30% of newborn need phototherapy.  
Management of neonatal jaundice was revolutionized by use of  
phototherapy which has reduced the need of exchange transfusion and  
sequlae of bilirubin induced brain damage. Despite this effective   therapy  
there is still difficulty in bringing down duration of  phototherapy and 
there is still need of exchange transfusion in  cases  of hemolytic 
jaundice. This calls for need of adjunctive therapy to  overcome these 
shortcomings in phototherapy.  
 Clofibrate proposed to help in these avenues was tried in this  
clinical entity  in the later part of twentieth century . Studies earlier   tried 
clofibrate for non hemolytic jaundice. It is now studied to be  useful in 
cases of hemolytic jaundice.  
 This study had equal sex distribution and distribution  of blood  
group incompatibility  in either group. There were 55.55% of  male  
babies  in overall and this substantiates the fact male sex is a risk  factor 
for neonatal hyperbilirubinemia2 .In a study by Hamid et al  there was 
55.6% of male babies in overall enrolled  in the study with  57.8% and 
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53.3% of babies in clofibrate and control group  respectively, 
substantiating our observation of increased incidence of  
hyperbilirubinemia in male sex.   
 Sharafi et al   in their study   group had  42 % of babies  were male 
sex and 58 %  babies female sex in contrary  to our observation of more 
male babies in our study.  Sakha et al   in their study had 62 % of male  
babies and  38 % female babies  and this study was in concurrence with 
our observation of increased babies of male sex. 
  There were 40 babies in this study with  blood group 
incompatibility accounting for 20.2 % of babies with  hyperbilirubinemia 
. With  judicious and wide coverage of Rh  incompatible pregnancy  with 
anti D globulin has reduced the  occurrence of this entity.  22.2% and 
14.1% of patients were with  ABO incompatibility in clofibrate and 
phototherapy group  respectively. The frequency of Rh incompatibility in 
Indian  population is 5% and their presentation with hemolytic disease of  
newborn has come down with use of  anti D usage. Incidence of   
fetomaternal ABO incompatibility is 20 -25% ,but their presentation  with 
pathological jaundice is seen in one in ten such babies . This is  because  
ABO antigens are weak antigens  and are of carbohydrate  class inducing 
antibodies weakly and  their antigens are secretory  antigen which help in 
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binding free antibodies, thereby reducing the  load  of antibody available 
for hemolysis.    
 The hours of life and the bilirubin value at onset of  phototherapy 
was  similar and statistically insignificant in either  groups. There was no 
statistical difference in peak bilirubin value in  either groups and it is 
found that bilirubin value did not increase further after start of  
phototherapy  in either groups  substantiating the  fact phototherapy is 
effective mode of treatment in neonatal jaundice.  Failure of phototherapy 
occurred only in 1 case which had ABO  incompatibility but it was 
statistically insignificant. But this data still  indicates that failure of 
phototherapy can still occur in phototherapy  receiving  babies especially 
in babies with blood group  incompatibility. 
 The mean age of presentation in a study by  morteza et al was  3.2 
days  and the bilirubin at start of phototherapy  was20.6 mg/dl .The mean 
age at start of therapy in our study was  58.91+/-18 hrs and  60.54+/-16 
hours in clofibrate and phototherapy  groups respectively. The early hours 
of life at  presentation of babies  is due to early referral of extramural 
babies and predominance of intramural  babies  helping in early initiation 
of phototherapy There  was  83% of patients in age group of 24 to 72 
hours . There is  no  statistically significant difference in either group. 
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 Habibi et al  in their study had their patients presenting at mean age 
of 74 hours in phototherapy group and  at 76 hours  in clofibrate group, 
which is in concurrence  with our study.  Moslehi et al in their study had 
mean age at presentation  of  126 hours in clofibrate group  and 128 hours 
in phototherapy group. Their  study had significantly delayed presentation 
age,  which may be because of failure to include blood group 
incompatibility  which is one of the common causes to present early with 
significant jaundice  and failure to include these cases could explain the 
possibility  of delayed presentation. 
 Moslehi et al had mean duration  of phototherapy  of 25 hoursin 
phototherapy group and 16  hours in clofibrate group and this could be 
because of delayed age of presentation  for treatment and failure to 
include babies with blood group incompatibility , as these are the group 
that may need prolonged duration of phototherapy. 
 The mean duration of phototherapy is 40.73 hours and 50.85  hours 
in clofibrate and  phototherapy group respectively . The mean  duration 
was statistically significant with  p value < 0.001. The  mean time needed 
for phototherapy in Clofibrate group  was38.8  hours   and it was  
statistically significantly lower than  control group  with  68.7 hours  by 
study done by hamid et al involving 90 children.  
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 In clofibrate  group71% of patients needed phototherapy for   
24- 48 hours. There was  statistically significant reduction in duration  of 
phototherapy in different time intervals of phototherapy   on  comparison 
of  two groups.  
 Peak bilirubin values were 18.63 and 18.25 mg/dl in clofibrate  and 
phototherapy groups respectively. There was no statistical  significance in 
either groups of patient. The mean bilirubin values   were 18.4 mg/dl in 
either groups by hamida et al.  Bilirubin values  failed to increase with 
phototherapy suggesting the effectiveness of  phototherapy.   There was 
94% and 96% of patients in clofibrate group and  phototherapy group 
respectively  with bilirubin in range 15 -20 mg/dl respectively.   
 Eghbalian et al in their had provided data with peak bilirubin of 
20.2 mg/dl in either group which is significantly more than our study.  
This study does not  provide data  on mean age of presentation   and this 
could not be explained.   
 Fallah et al had peak bilirubin of 19.4 mg/dl in clofibrate group and 
19.57 mg/dl in phototherapy group which is comparable to our data.  This 
study had included only term babies and normal birth weight babies only 
without any blood group incompatibility. 
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 There was  no statistical significance in relation between hours of 
life  and peak bilirubin values in either groups.  
 The relation of peak bilirubin and duration of phototherapy was  
analysed and there was statistical significant difference in either  groups 
in patient with peak bilirubin  in 15 -20 mg/dl range with p  value< 0.001. 
There was no statististical significance in patients with  peak bilirubin in 
range 10 -15 mg /dl, 20-25  mg/dl. 
 There was failure of phototherapy in one patient with peak  
bilirubin in phototherapy with needing exchange transfusion and this  was 
statistically insignificant in either groups. During follow up  there was no 
adverse effects in either group.  
 In present study there was statistically significant difference in  
patient in duration of phototherapy and duration of phototherapy in  
patients with peak bilirubin values between in 15 -20 mg/dl between  the  
two group.  
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CONCLUSION 
 Neonatal jaundice is a common entity with effective therapy in  the 
form of phototherapy, but still the duration of phototherapy is  quite 
prolonged affecting maternal  and infant bonding.  To reduce  the 
duration of phototherapy adjunctive drugs has been tried . In this  process 
clofibrate has come a long way and in this study it has  reduced the 
duration of phototherapy by significant duration.  There  was no adverse 
effect during its use. Clofibrate is effective in  lowering bilirubin at single 
low dose of 25 mg/kg at start of  phototherapy.  To support the use of this 
drug further studies on  safety with long term follow up and use in sick 
term babies and stable  preterm babies are needed. 
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 MASTER CHART 
S. 
No. Name IPNo Sex Group 
Hrs of Life at 
start of 
phototheraphy 
mat gp baby gp bw initial bilirubin peakbil 
duration 
of 
photother-
aphy 
Coombs Peripheral 
smear 
Compli-
cations 
1. b/pounu 11516 M c+pt 56hrs o+ b+ 2.6 19.4 19.4 48 hrs coombs+ spherocytes+ nil 
2. b/nathiya 11684 M pt 62hrs b+ b+ 3 18.2 18.2 72 hrs -ve coombs Ps n  nil 
3. b/rathidevi 11714 F c+pt 51hrs b+ ab+ 3.6 17.9 17.9 36hrs -ve coombs  psn nil 
4. b/nirmala 11963 M pt 60hrs o+ a+ 2.9 17.8 17.8 60 hrs coombs + spherocytes+ nil 
5. b/bhavani 12005 F pt 66hrs b+ b+ 3 18.9 18.9 72hrs -ve coombs  Ps n ni; 
6. b/amudha 12125 M pt 54hrs a+ a+ 2.8 17.8 17.8 36hrs -ve coombs  Ps n nil 
7. b/kanchana 12303 M c+pt 58 hrs a+ ab+ 2.5 18.2 18.2 48hrs -ve coombs psn  nil 
8. b/radha 12083 F c+pt 48 hrs o+ a+ 2.7 21 21 48 hrs coombs-ve ps n nil 
9. b/sumathy 12170 F c+pt 60hrs a+ ab+ 2.8 18.7 18.7 24hrs -ve coombs  psn nil 
10. b/zeenath 12241 F pt 55hrs o+ b+ 2.75 18.1 18.1 48hrs coombs-ve ps n nil 
11. b/shobana 12173 M c+pt 53 hrs b+ b+ 3.2 18.8 18.8 24hrs -ve coombs psn  nil 
12. b/renuka 12537 M pt 60hrs a+ ab+ 2.9 18.4 18.4 36hrs -ve coombs  Psn nil 
13. b/sujatha 12649 M pt 45hrs a+ ab+ 2.6 18.1 18.1 48 hrs -ve coombs  Ps n nil 
14. b/mallika 12614 F c+pt 42 hrs o+ o+ 3.1 17.7 17.7 36hrs -ve coombs  Psn  nil 
15. b/ramya 12713 F c+pt 56hrs o+ a+ 2.85 19.7 19.7 36hrs coombs-ve ps n nil 
16. b/sharmila 12753 F pt 66hrs o+ o+ 3.35 18.7 18.7 48hrs -ve coombs  Ps n nil 
17. b/vetriselvi 12795 M pt 68hrs a+ ab+ 3.3 18.6 18.6 48hrs -ve coombs  Ps n nil 
18. b/deepalakshmi 12793 M c+pt 60hrs a+ a+ 3.5 19.4 19.4 36hrs -ve coombs  Psn  nil 
19. b/muthuselvi 12870 M  c+pt 40hrs o+ a+ 2.9 18.7 18.7 36 hrs coombs-ve ps n nil 
20. b/selvi 12466 M pt 70hrs a+ ab+ 3.2 17.6 17.6 48hrs -ve coombs  Ps n nil 
21. b/vetrikodi 12997 F c+pt 64hrs a+ a+ 2.9 18.8 18.8 36hrs -ve coombs  Psn  nil 
22. b/velvizhi 13627 F c+pt 73hrs b+ ab+ 3.1 17.8 17.8 12hrs -ve coombs Ps n  nil 
23. b/valarmathi 13118 M c+pt 67hrs o+ a 2.9 19.3 19.3 36hrs coombs -ve ps n nil 
24. b/mullaselvib/chinna
mmal 12764 M pt 44hrs b+ ab+ 3.4 18.2 18.2 54 hrs -ve coombs  Ps n nil 
25. b/chinnammal 13058 F pt 61hrs ab+ b+ 3.1 18.4 18.4 48hrs -ve coombs  Ps n nil 
26. b/sumathi 13184 F pt 76hrs a+ a+ 3.1 18.6 18.6 48hrs -ve coombs  Ps n nil 
27. b/bhuvana 13274 M pt 49hrs a+ o+ 3.2 18.8 18.8 36hrs -ve coombs  Ps n nil 
28. b/sumithra 13312 M pt 70hrs a+ a+ 2.8 19.2 19.2 48hrs -ve coombs  Ps n nil 
29. b/vani 13287 M c+pt 66hrs a+ o+ 2.6 18.2 18.2 48hrs -ve coombs  Ps n nil 
30. b/arunaiselvi 13188 F c+pt 79hrs b+ b+ 2.8 17.8 17.8 12hrs -ve coombs  Ps n nil 
31. b/vasanthavalli 13234 M c+pt 66hrs b+ a+ 3 18.3 18.3 24hrs -ve coombs  Ps n nil 
32. b/jeyalakshmi 13420 M pt 60hrs o+ o+ 3 17.6 17.6 36hrs -ve coombs Ps n  nil 
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33. b/nirosha 13429 M c+pt 58hrs 0- o+ 2.6 18.4 18.4 36hrs coombs -ve ps n nil 
34. b/nandhini 13444 M pt 67hrs b+ a+ 3.4 17.9 17.9 48hrs -ve coombs  Ps n  nil 
35. b/thenmozhi 13569 M c+pt 43hrs b+ ab+ 2.6 18.6 18.6 36hrs -ve coombs  Ps n nil 
36. b/valarmathi 13604 M pt 62hrs ab+ b+ 2.5 18.1 18.1 48hrs -ve coombs  Psn nil 
37. b/bharani 17143 F pt 48hrs ab+ b+ 2.7 17.5 17.5 36hrs -ve coombs  Ps n nil 
38. b/sangeetha 17177 F c+pt 60hrs a+ ab+ 2.7 18.8 18.8 36hrs -ve coombs  Ps n nil 
39. b/suganya 17101 F c+pt 60hrs b- b+ 2.5 18.5 18.5 48hrs coombs-ve ps n nil 
40. b/girija 17219 F pt 48hrs ab+ o+ 3.4 16.9 16.9 36hrs -ve coombs  Ps n nil 
41. b/orajakumari 16898 M c+pt 84hrs o+ a+ 2.75 19.8 19.8 36hrs coombs +ve spherocytes+ nil 
42. b/oshezaz 17406 M pt 72 hrs ab+ a+ 2.8 18.5 18.5 48hrs -ve coombs Ps n  nil 
43. b/o revathi 18307 M c+pt 48hrs ab+ ab+ 3.4 18.3 18.3 38hrs -ve coombs  Ps n nil 
44. b/osathya 18181 F pt 60hrs a+ o+ 3 19.2 19.2 60hrs -ve .coomb.s  Ps n nil 
45. b/osaranya 17096 F c+pt 72hrs o+ a+ 2.7 18.8 18.8 36hrs coombs+ve spherocytes+ nil 
46. b/oamul 18654 F c+pt 60hrs ab+ o+ 2.7 19.4 19.4 30hrs -ve coombs  Ps n nil 
47. b/o devi 18098 F pt 64hrs 0- a- 3.5 17.8 17.8 48hrs -ve coombs  Ps n nil 
48. b/onaseema 18744 M pt 48hrs o+ a+ 3.2 18.7 18.7 72hrs coombs-ve ps n nil 
49. b/osudha 17429 M pt 51hrs a+ ab+ 2.5 17.9 17.9 60hrs -ve coombs  Ps n nil 
50. b/onithya 17266 F c+pt 60hrs o+ a+ 2.7 18.3 18.3 36hrs coombs+ve spherocytes+ nil 
51. b/oshanthi 17433 F c+pt 40hrs o+ o+ 2.8 18.9 18.9 30hrs -ve coombs  Ps n nil 
52. b/ogeetha 17489 F pt 60hrs a+ 0+ 3.4 17.9 17.9 48hrs -ve coombs Ps n nil 
53. b/oeswari 17621 F c+pt 48hrs o+ a+ 2.6 18.3 18.3 36hrs coombs-ve ps n nil 
54. b/ohemalatha 17677 M pt 60hrs ab+ o+ 2.7 18.7 18.7 60hrs -ve coombs Ps n  nil 
55. b/orevathy 19629 M c+pt 54hrs o+ b+ 3.3 17.4 17.4 24hrs coombs-ve ps n nil 
56. b/ochitra 19767 M c+pt 36hrs a+ o+ 3.4 15.4 15.4 36hrs -ve coombs  Ps n nil 
57. b/othavapriya 20273 F pt 30hrs o+ a+ 2.5 18.7 18.7 60hrs coomns+ve spherocytes+ nil 
58. b/otharaichitra 21092 F c+pt 108hrs o+ a+ 2.7 19.7 19.7 30hrs coombs-ve ps n nil 
59. b/osathya 20317 F pt 90hrs o+ b+ 2.5 18.9 18.9 30hrs coombs-ve ps n nil 
60. b/o devi 21017 M pt 70hrs o- b+ 2.8 18.9 18.9 48hrs coombs-ve ps n nil 
61. b/olavaya 20216 M c+pt 60hrs o+ o+ 4.1 18.8 18.8 48hrs -ve coombs  Ps n nil 
62. b/omanju 20232 M c+pt 84hrs a+ ab+ 3.3 19.2 19.2 48hrs -ve coombs  Ps n nil 
63. b/oporkani 20832 F pt 72hrs b+ o+ 3.7 19.1 19.1 60hrs -ve coombs  psn nil 
64. b/otamilarasi 21129 F c+pt 72hrs o+ a+ 2.8 18.4 18.4 48hrs coombs+ve ps n nil 
65. b/olakshmi 20931 M pt 70hrs o+ a+ 2.6 18.3 18.3 60hrs coombs-ve ps n nil 
66. b/odharanichitra 20273 F pt 54hrs o+ a+ 2.7 18.2 18.2 60hrs coombs-ve ps n nil  
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67. b/o poongothai 21113 M pt 56hrs ab+ a+ 2.8 18.8 18.8 42h -ve coombs  Ps n nil 
68. b/odhavapriya 21092 M c+pt 48hrs o+ o+ 2.8 17.9 17.9 48hrs -ve coombs  Ps n  nil 
69. b/omenaka 21252 F c+pt 50hrs o+ o+ 2.5 18.8 18.8 36hrs -ve coombs  Ps n nil 
70. b/odhanalakshmi 29730 F c+pt 60hrs o+ o+ 2.9 18.6 18.7 36hrs -ve coombs  Ps n nil 
71. b/oanandhi 21823 M pt 70hrs o+ o+ 3.2 17.9 17.9 48hrs -ve .coombs  Ps n nil 
72. b/oradhidevi 21513 M c+pt 62hrs o+ a+ 3.2 18.5 18.5 36hrs coombs-ve ps n nil 
73. b/osangeetha 21850 F pt 66hrs o+ o+ 2.5 17.9 17.9 48hrs -ve coombs  Ps n nil 
74. b/gomathi 22039 F c+pt 84hrs ab+ o+ 2.9 18.2 18.2 36hrs -ve coombs  Ps n nil 
75. b/odhanalakshmi 22179 F c+pt 72hrs a+ a+ 2.85 18.3 18.3 48hrs -ve coombs  Ps n nil 
76. b/ovani 22470 M pt 60hrs ab+ a+ 2.5 18.9 18.9 48hrs -ve coombs  Ps n nil 
77. b/osafrin 22670 M pt 72hrs b+ o+ 3 17.8 17.8 36hrs -ve coombs  Ps n nil 
78. b/obhuvana 22847 M c+pt 60hrs o+ a+ 3 17.9 17.9 48hrs -v e coombs  Ps n nil 
79. b/osasikala 23274 M pt 48hrs a+ ab+ 3.2 18.5 18.5 48hrs coombs-ve ps n nil 
80. b/omaheshwari 23222 F c+pt 48hrs a+ a+ 3.1 17.9 17.9 36hrs -ve coombs  Ps n nil 
81. b/osudha 22365 M pt 49hrs a+ ab+ 3.4 18.9 18.9 54h -ve coombs  Ps n nil 
82. b/ojeyanthi 22600 F pt 84hrs ab+ b+ 2.7 17.8 17.8 36hrs -ve coombs  Ps n nil 
83. b/o amala 23081 F pt 84 hrs a+ a+ 3.1 19.2 19.2 48hrs -ve coombs  Ps n  Nil 
84. b/o geetha 23826 M pt 80 hrs b+ o+ 2.75 19 19 48hrs -ve coombs  Ps n  Nil 
85. b/omariammal 24152 M pt 66hrs b+ b+ 2.5 17.9 17.9 36hrs -ve coombs  Ps n  Nil 
86. b/ousha 24324 M c+pt 70hrs o+ b+ 2.9 18.8 18.8 36hrs coombs-ve ps n  Nil 
87. b/ovelammal 24276 F pt 72hrs b+ ab+ 3.5 17.9 17.9 36hrs -ve coombs  Ps n  Nil 
88. b/osaraswathy 24288 F pt 69hrs o+ a+ 3.6 18.2 18.2 48hrs coombs + spherocytes+  Nil 
89. b/o nirosha  24326 M pt 80hrs ab+ a+ 2.9 18.2 18.2 36hrs -ve coombs  Ps n  Nil 
90. b/oazhagurani 24412 M c+pt 84hrs o+ o+ 3.4 18.7 18.7 36hrs -ve coombs  Ps n  Nil 
91. b/o vanaroja 24480 M c+pt 80hrs o+ a+ 3 19.2 19.2 48hrs coombs - ps n  Nil 
92. b/orizwana 24375 F c+pt 76hrs b+ o+ 3.2 18.9 18.9 36hrs -ve coombs  Ps n  Nil 
93. b/o sumathi 25607 M pt 79hrs ab+ a+ 2.75 17.9 17.9 36hrs -ve coombs Ps n   nil 
94. b/osivakami 25405 M c+pt 68hrs o- o+ 2.6 18.5 18.5 48hrs coombs- ps n  Nil 
95. b/okalaivani 25709 M c+pt 75hrs a+ a+ 3 18.8 18.8 36hrs Coombs –ve    Nil 
96. b/ousha 25137 F pt 70hrs a+ o+ 3.2 18.2 18.2 48hrs -ve .,coombs  Ps n  Nil 
97. b/okalapana 26103 M pt 66hrs a+ o+ 2.9 18 18 48hrs -.ve coombs  Ps n  Nil 
98. b/osaraswathy 26225 M pt 71hrs o+ b+ 2.5 18.5 18.5 60hrs coombs+ spherocytes+  Nil 
99. b/osrilekha 25828 F c+pt 63hrs a+ ab+ 3.25 18.9 18.9 48hrs -ve coombs  Ps n  Nil 
100. b/orosy 26352 M c+pt 68hrs a+ o+ 3.5 17.7 17.7 24hrs -ve coombs  Ps n  Nil 
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101. b/omary  26049 M c+pt 69hrs ab+ a+ 2.75 17.5 17.5 24hrs -ve coombs  Ps n  Nil 
102. b/ochitra 26291 M pt 70hrs o+ o+ 2.6 18.1 18.1 48hrs -ve coombs  Ps n  Nil 
103. b/oanbarasi 24413 F c+pt 68hrs b+ b+ 2.5 18.5 18.5 36hrs -ve coombs  P sn  Nil 
104. b/oaruna 25523 M pt 70hrs ab+ a+ 2.7 17.9 17.9 48hrs -ve coombs  Ps n  Nil 
105. b/obhuvana 27223 M pt 66hrs ab+ b+ 2.75 16.7 16.7 36hrs -ve coombs  P s n  Nil 
106. b/oramani 27262 M c+pt 70hrs ab+ a+ 2.5 17.7 17.7 24hrs -ve coombs  Ps n  Nil 
107. b/oanitha 26938 F pt 78hrs a+ a+ 2.75 18.1 18.5 60hrs -ve coombs  Ps n  Nil 
108. b/odevi 27237 F c+pt 78hrs ab+ a+ 3 18.5 18.5 48hrs -ve coombs  Ps n  Nil 
109. b/ouma 27470 M c+pt 66hrs a+ ab+ 2.75 17.9 17.9 24hrs -ve coombs  Ps n  Nil 
110. b/o chellammal 27478 F pt 74hrs o- o+ 2.7 17.3 17.8 60hrs coombs- ps n  Nil 
111. b/oamsavathy 27504 M c+pt 46hrs a+ o+ 2.5 18.1 18.1 48hrs -ve coombs  Ps n  Nil 
112. b/o gunasundari 27317 F pt 68hrs a+ a+ 3.1 18 18 54hrs -ve coombs  Ps n  Nil 
113. b/oumamaheshwari 27239 M pt 82hrs a+ ab+ 2.6 19.8 19.8 48hrs -ve coombs  Ps n  Nil 
114. b/osanthanalakshmi 27511 M c+pt 51hrs a+ a+ 2.5 18.4 18.9 48hrs -ve coombs  Ps n  Nil 
115. b/onirmala 27347 M c+pt 80hrs o- b+ 3 19.2 19.2 48hrs -ve coombs  Ps n  Nil 
116. b/ovimala 28002 M pt 60hrs o+ b+ 3.1 18.7 18.7 48hrs -ve coombs  Ps n  Nil 
117. b/omanimegalai 27630 M pt 71hrs a+ ab+ 3 18.5 18.5 36hrs -ve coombs  Ps n  Nil 
118. 
b/obentica sarala 27956 F pt 49hrs o+ a+ 3.7 21.8 25.4 96hrs coombs+ve 
spherocytes 
+  
exchange 
done  Nil 
119. b/okalaiselvi 27807 M c+pt 75hrs ab+ b+ 2.75 19.4 19.5 48hrs -ve .coombs  Ps n  Nil 
120. b/onalini 27853 M c+pt 65hrs o+ o+ 3 19.8 19.8 48hrs -ve coombs  Ps n  Nil 
121. b/orevathy 27798 M pt 70hrs o+ o+ 3 18.4 18.4 60hrs -ve coombs  Ps n  Nil 
122. b/oshakila 28287 F pt 66hrs a+ ab+ 3.5 18.8 18.8 60hrs -ve coombs  Ps n  Nil 
123. b/omanjula 28491 F c+pt 53hrs b+ o+ 2.8 19.4 19.4 36hrs -ve coombs  Ps n  Nil 
124. b/omadhavi 28969 M c+pt 66hrs o+ ab+ 2.5 19.1 19.1 36hrs -ve coombs  Ps n  Nil 
125. bokalpana 29191 M c+pt 73hrs o+ o+ 2.8 18.5 18.5 30hrs -ve coombs  Ps n  Nil 
126. b/olakshmi 29464 M pt 77hrs a+ o+ 3 19.3 19.3 48hrs -ve coombs  Ps n  Nil 
127. b/o kannaki 29561 M pt 79hrs a+ o+ 3.4 18.7 18.7 60hrs -ve coombs  Ps n  Nil 
128. b/okamala 29576 M c+pt 83hrs o+ a+ 3.2 19.3 19.3 48hrs coombs-ve ps n  Nil 
129. b/omallika 29587 F pt 67hrs a+ a+ 3.1 18.8 18.8 48hrs -ve coombs  Ps n  Nil 
130. b/onalina 29621 M c+pt 56hrs a+ o+ 3.2 19.4 19.4 48hrs -ve coombs  Ps n  Nil 
131. b/ojanani 29643 F pt 65hrs a+ a+ 3.1 18.9 18.9 60hrs -ve coombs  Ps n  Nil 
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132. b/osundari 29663 F pt 48hrs o+ o+ 2.6 18.5 18.5 60hrs -ve coombs  Ps n  Nil 
133. b/osujatha 29673 F pt 53hrs a+ o+ 2.7 18.9 18.9 48hrs -ve coombs  Ps n  Nil 
134. b/oanjali 29698 M c+pt 49hrs a+ o+ 2.9 18.6 18.6 54hrs -ve coombs  Ps n  Nil 
135. b/obarathi 29689 M c+pt 43hrs a+ a+ 2.8 19.4 19.4 54hrs -ve coombs  Ps n  Nil 
136. b/okumare 29732 M pt 49hrs o+ ab+ 3.2 18.9 18.9 48hrs -ve coombs  Ps n  Nil 
137. b/osandhya 29745 F pt 55hrs a+ ab+ 3.5 18.9 18.9 60hrs -ve coombs  Ps n  Nil 
138. b/osaranya 29752 M pt 43hrs a+ a+ 3.1 19.4 19.4 72hrs -ve coombs  Ps n  Nil 
139. b/omallika 29761 F c+pt 42hrs ab+ a+ 2.8 18.9 18.9 60hrs -ve coombs  Ps n  Nil 
140. b/opriya 29769 F c+pt 48hrs o+ b+ 2.7 19.1 19.1 48hrs -ve coombs  Ps n  Nil 
141. b/osalini 29771 M c+pt 61hrs b+ b+ 2.5 18.9 18.9 48hrs -ve coombs  Ps n   Nil 
142. b/oyamini 29789 M pt 38hrs o+ 0+ 2.9 18.3 18.3 60hrs -ve coombs  Ps n  Nil 
143. b/obeula 29801 F pt 45hrs b+ o+ 2.7 18.6 18.6 48hrs -ve coombs Ps n   Nil 
144. b/ovanaja 29832 M c+pt 49hrs o+ a+ 3.2 20.1 20.1 60hrs coombs-ve ps n  Nil 
145. b/oshenbagam 29898 F c+pt 54hrs b+ o+ 2.7 19.3 19.3 36hrs -ve coombs  Ps n  Nil 
146. b/osunila 29906 M pt 60hrs ab+ o+ 3.1 18.1 18.1 48hrs -ve coombs  Ps n  Nil 
147. b/ovennila 29945 F pt 64hrs a+ o+ 2.7 18.6 18.6 48hrs -ve coombs  Ps n  Nil 
148. b/oalamelu 29998 M c+pt 46hrs a+ o+ 3.1 18.6 18.6 36hrs -ve coombs  Ps n  Nil 
149. b/oandal 30021 F c+pt 48hrs o+ a+ 3.5 19.6 19.6 48hrs coombs +ve spherocytes+  Nil 
150. b/o nancy 30072 M pt 39hrs a+ o+ 3.2 18.9 18.9 60hrs -ve coombs  Ps n  Nil 
151. b/osulaima 30121 M pt 49hrs a+ a+ 2.6 18.7 18.7 48hrs -ve coombs  Ps n  Nil 
152. b/ovelankanni 30165 M c+pt 59h o+ o+ 3.1 19.1 19.1 36hrs -ve coombs  Ps n  Nil 
153. b/okumari 30198 F c+pt 65hrs a+ ab+ 2.5 18.4 18.4 36hrs -ve coombs  Ps n  Nil 
154. b/o shobana 30212 F c+pt 32h a+ a- 3.1 17.3 17.3 48hrs -ve coombs  Ps n  Nil 
155. b/ojemila 30254 F pt 46hrs o+ ab+ 3 18.4 18.4 56hrs -ve coombs  Psn   Nil 
156. b/o mahalaksmi 30298 M pt 54hrs a+ a+ 3.2 18.9 18.9 48hrs -ve coombs  Ps n  nil 
157. b/osandhya 30312 F c+pt 34h a+ a+ 2.8 18.2 18.2 60hrs -ve coombs  Ps n  Nil 
158. b/ocatherine 30345 M c+pt 47hrs o+ ab+ 3.1 19.1 19.1 48hrs -ve coombs  Ps n  Nil 
159. b/odivya 30398 F c+pt 65hrs a+ ab+ 2.9 18.9 18.9 36hrs -ve coombs  Ps n  Nil 
160. b/okanaga 30421 F c+pt 47hrs a+ a+ 2.6 17.2 17.2 24hrs -ve coombs Ps n    Nil 
161. b/oganga 30512 M pt 54hrs a+ o+ 3.1 18.8 18.8 36hrs -ve coombs  Ps n  Nil 
162. b/o gunavathi 30545 F pt 65hrs a+ ab+ 2.9 18.1 18.1 54hrs -ve  coombs  Ps n  Nil 
163. b/okumari 30598 M c+pt 49hrs ab+ a+ 3.6 18.2 18.2 48hrs -ve coombs  Ps n  Nil 
164. b/oparvathi 30621 F c+pt 56hrs a+ ab+ 2.8 18.7 18.7 36hrs -ve .coombs  Ps n  Nil 
165. b/olaxmi 30671 F c+pt 54hrs b+ ab+ 3.1 19.2 19.3 48hrs -ve coombs  Ps n  Nil 
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166. b/o noorjahan 30728 M pt 39hrs o+ ab+ 3.3 18.4 18.4 60hrs -ve coombs  Ps n  Nil 
167. b/oilayapriya 30739 M pt 45hrs a+ ab+ 2.6 17.9 17.9 48hrs -ve coombs  Ps n  Nil 
168. b/ojunaina 30789 M c+pt 38hrs o+ a+ 3.2 17.3 17.3 48hrs -ve coombs  Ps n  Nil 
169. b/ooviya 30833 F c+pt 48hrs ab+ a+ 3 18.8 18.8 36hrs -ve coombs  Ps n  Nil 
170. b/oramya 30894 M pt 56hrs ab+ a+ 3.4 18.1 18.1 54hrs -ve coombs  Psn  Nil 
171. b/ofathima 30912 F pt 47hrs b+ ab+ 3.1 18.9 18.9 54hrs -ve coombs  Ps n  Nil 
172. b/opunitha 30988 F pt 59h a+ a+ 3.4 17.9 17.9 60hrs -ve coombs  Ps n  Nil 
173. b/orahima 31092 M c+pt 43hrs a+ ab+ 2.6 17.6 17.6 36hrs -ve coombs  Ps n  Nii 
174. b/o tamilselvi 31043 M c+pt 48hrs a+ a+ 2.9 20.1 20.1 48hrs -ve coombs Ps n   Nil 
175. b/o gayathri 31127 F c+pt 78hrs a+ ab+ 3.1 17.9 17.9 24hrs -ve coombs  Ps n  Nil 
176. b/ogeetha 31189 M c+pt 40hrs a+ a+ 2.7 18.2 18.2 36hrs -ve coombs  Psn  Nil 
177. b/ouma 31298 M pt 49hrs b+ ab+ 2.8 18.9 18.9 54hrs -ve coombs  Ps n  Nil 
178. b/ovanitha 31321 M c+pt 56hrs a+ a+ 3.4 19.4 19.4 60hrs -ve coombs  Ps n  Nil 
179. b/okalyani 31437 F pt 67hrs ab+ a+ 2.8 18.6 18.6 48hrs -ve coombs  Ps n  Nil 
180. b/opavithra 31469 M c+pt 74hrs ab+ a+ 3.2 19.3 19.3 48hrs -ve coombs  Ps n  nil 
181. b/ochinnamma 31543 F c+pt 49hrs a+ a+ 2.8 18.9 18.9 36hrs -ve coombs  Ps n  Nil 
182. b/orekha 31598 F pt 52hrs a+ ab+ 3.2 18.4 18.4 48hrs -ve coombs  Ps n  Nil 
183. b/olavanya 31643 M pt 73hrs a+ a+ 2.6 2.6 17.9 48hrs -ve coombs  Ps n  Nil 
184. b/okamala 31678 F c+pt 46hrs ab+ b+ 2.8 18.2 18.2 60hrs -ve coombs  Ps n   Nil 
185. bokalpana 31776 F pt 43hrs o+ o+ 3.1 17.8 17.9 48hrs -ve coombs  Ps n  Nil 
186. b/okancana 31798 M c+pt 49hrs a+ o+ 2.8 18.1 18.1 36hrs -ve .coombs  Ps n  Nil 
187. b/onaveena 31854 F c+pt 56hrs b+ a+ 3.1 18.7 18.7 48hrs -ve coombs  Ps n  Nil 
188. b/ochellamma 31987 M pt 39hrs o+ ab+ 2.8 18.7 18.7 60hrs -ve coombs  Ps n  Nil 
189. b/ogomati 31954 M pt 47hrs a+ ab+ 2.6 18.6 18.6 48hrs -ve coombs  Ps n  nil 
190. b/osridevi 32003 M pt 56hrs ab+ a+ 2.7 17.8 17.8 54hrs -ve coombs  Ps n  Nil 
191. b/ojayanthi 32112 F c+pt 47hrs a+ ab+ 2.9 18.1 18.1 36hrs -ve coombs  psn  Nil 
192. b/okasturi 32227 F c+pt 56hrs a+ o+ 2.7 18.9 18.9 48hrs -ve coombs  Psn  Nil 
193. b/oambiga 32298 M c+pt 35hrs ab+ a+ 3.2 17.9 17.9 36hrs -ve coombs Ps n   Nil 
194. b/o damayanthi 32343 F pt 48hrs a+ ab+ 2.8 17.3 17.3 48hrs -ve coombs psn  Nil 
195. b/oarthi 32432 F pt 65hrs o+ ab+ 3.1 18.5 18.5 48hrs -ve coombs Ps n   Nil 
196. b/odeenarani 32457 M c+pt 42hrs a+ a+ 3.4 17.9 17.9 36hrs -ve coombs Ps n   Nil 
197. b/oindu 32547 F c+pt 46hrs a+ ab+ 3.2 18.7 18.7 48hrs -ve coombs  Ps n  Nil 
198. b/ogeetha 32654 M pt 39hrs o+ a+ 3.6 19.1 19.1 60hrs coombs-ve ps n  Nil 
 
